Lilly to launch generic of its insulin Humalog, cutting list price in half

Introduction of an authorized generic, though, may not dispel criticism of Lilly's pricing, which has come under scrutiny in recent years. 

By Ned Pagliarulo , Andrew Dunn • March 4, 2019

AbbVie, Akcea benefit from latest CHMP recommendations

Risankizumab and volanesorsen​, which would be marketed as Skyrizi and Waylivra, were among eight drugs that got committee support.

By Jacob Bell • March 1, 2019

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Roche wins US approval of more convenient Herceptin

Treatment with subcutaneous Herceptin takes just a few minutes, rather than the sometimes hour and a half needed to administer the breast cancer drug intravenously.

By Ned Pagliarulo • March 1, 2019

So far, so good for Alexion's Soliris follow-on

Alexion is working to convert PNH patients to its newer Ultomiris, preparing for a future with biosimilar competition.

By Jacob Bell • Feb. 28, 2019

At Senate hearing, pharma shows split on biosimilars

Merck & Co. and Pfizer are eager to see biosimilar uptake encouraged, a position fellow big pharma J&J doesn't appear to share. 

By Ned Pagliarulo • Feb. 27, 2019

Early Epidiolex sales push up GW Pharma's stock

The cannabis-based epilepsy therapy got off to a strong commercial start in the U.S., analysts said, although the drug's roll-out is still in early days.

By Andrew Dunn • Feb. 27, 2019

How lawmakers could pressure top pharma execs in Senate hearing

Here's a guide to the political pressure points for each of the seven drug companies in front of the Senate Finance Committee today.

By Ned Pagliarulo • Feb. 25, 2019

Intercept stock drop reflects the high bar set for NASH drugs

Though Intercept's drug Ocaliva did score the first Phase 3 victory against the fatty liver disease, investors still appear skeptical of the drug's prospects.

By Jacob Bell • Feb. 22, 2019

Dr. Reddy's relaunches Suboxone generic after court victories

A legal battle had stalled entry of Dr. Reddy's copy, which will now challenge Indivior's opioid dependence treatment in the U.S. 

By Kristin Jensen • Updated Feb. 22, 2019

Sanofi handed payers nearly $12B in drug rebates last year

That's why, despite increasing the U.S. list price on 35 of its 76 prescription drugs, the French pharma reported an average net price decline of 8% in 2018.

By Ned Pagliarulo • Feb. 21, 2019

US healthcare spending growth to hit 5.5% by 2027, CMS predicts

The ballooning American healthcare bill will outstrip GDP growth over the next decade, according to an annual government report.

By Rebecca Pifer • Feb. 20, 2019

CMS unveils CAR-T proposal, with emphasis on patient outcomes

High price tags and a potential one-time administration have challenged CMS to figure out reimbursement for CAR-T cell therapies.

By Jacob Bell • Feb. 15, 2019

Payers divided over best value-based payment model, survey finds

A new HealthEdge survey of 151 health insurance execs highlighted ongoing challenges to adoption, although utilization appears common.

By Les Masterson • Feb. 14, 2019

Mylan launches Advair generic at 70% discount

While a long time coming, Mylan's copycat version now looks set to take a bite out of GSK's respiratory drug sales.

By Suzanne Elvidge • Feb. 13, 2019

Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen

The drugmakers will make Praluent available for 60% less than the cholesterol drug's original price, a decision reflective of persistent commercial hurdles.

By Ned Pagliarulo • Feb. 11, 2019

Eylea's PANORAMA data give fuller view of efficacy in label expansion bid

Regeneron's blockbuster eye drug benefited certain patients with severe diabetic retinopathy, a market the big biotech is eager to break into.

By Jacob Bell • Feb. 11, 2019

J&J to disclose list prices in TV drug ads

Beginning in March, commercials for J&J's blockbuster blood thinner Xarelto will include list prices — a step beyond PhRMA's planned approach.

By Jacob Bell • Feb. 7, 2019

Mylan takes step toward knocking down key patent for Biogen's top seller

An inter partes review is under way for Tecfidera, though analysts predicted big hurdles remain to a generic of the multiple sclerosis drug.

By Jacob Bell • Feb. 7, 2019

Vertex fears its triplet will also face UK reimbursement battle

U.K. regulators have already been in contentious battles with the biotech over its two-drug regimens for cystic fibrosis.

By Jacob Bell • Feb. 6, 2019

Successful launch bolsters Libtayo's place as cornerstone therapy for Regeneron

The immunotherapy earned $15 million during its first quarter on the market, securing broad access across commercial and government insurance plans.

By Jacob Bell • Feb. 6, 2019

FDA draft lays out submission paths for combo products

Commissioner Scott Gottlieb said the agency will develop additional guidances outlining specific premarket considerations for combo products.

By David Lim • Feb. 6, 2019

Lilly lowers 2019 revenue hopes, citing Lartruvo failure

Lartruvo's clinical failure, pricing pressure and an $8 billion acquisition have caused Lilly to shift business expectations for 2019.

By Andrew Dunn • Feb. 6, 2019

Pharma is shuffling around jobs, but a skills gap threatens the process

Drugmakers have found difficulty luring employees who can work with the latest technologies away from the likes of Amazon and Google, for instance. 

By Jacob Bell • Feb. 4, 2019

In hiking prices, drugmakers show some signs of tempering increases

Analysts at Raymond James found pharma price increases last month to be somewhat smaller than in January 2018 — evidence, perhaps, of some newfound restraint.

By Andrew Dunn • Feb. 4, 2019

Does Merck need more than Keytruda?

The cancer drug's meteoric rise is responsible for most of Merck's growth, but analysts aren't sure if that's such a good thing.

By Jacob Bell • Feb. 1, 2019